Sigrid Therapeutics granted European patent covering the use of porous SiPore[®] silica particles as pharmaceutical or dietary active ingredients
Stockholm, Sweden March 7, 2022. Sigrid Therapeutics, a Swedish healthtech company specializing in the prevention and treatment of type-2 diabetes and obesity, today announced that the European Patent Office has granted the company patent EP2916852 titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s breakthrough, mesoporous silica particles (MSP)-based device which consists of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in the gut as a pharmaceutical and dietary